JP6646571B2 - 膵臓がんを検出するための方法および組成物 - Google Patents

膵臓がんを検出するための方法および組成物 Download PDF

Info

Publication number
JP6646571B2
JP6646571B2 JP2016502266A JP2016502266A JP6646571B2 JP 6646571 B2 JP6646571 B2 JP 6646571B2 JP 2016502266 A JP2016502266 A JP 2016502266A JP 2016502266 A JP2016502266 A JP 2016502266A JP 6646571 B2 JP6646571 B2 JP 6646571B2
Authority
JP
Japan
Prior art keywords
pancreatic cancer
subject
level
cancer biomarker
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016502266A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519285A (ja
JP2016519285A5 (enExample
Inventor
パンネル,ルイス・ケイ
ロッカー,ジャナ
Original Assignee
クリエイティクス エルエルシー
クリエイティクス エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリエイティクス エルエルシー, クリエイティクス エルエルシー filed Critical クリエイティクス エルエルシー
Publication of JP2016519285A publication Critical patent/JP2016519285A/ja
Publication of JP2016519285A5 publication Critical patent/JP2016519285A5/ja
Application granted granted Critical
Publication of JP6646571B2 publication Critical patent/JP6646571B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G01N33/57525
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57438Specifically defined cancers of liver, pancreas or kidney
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016502266A 2013-03-13 2014-03-13 膵臓がんを検出するための方法および組成物 Expired - Fee Related JP6646571B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780574P 2013-03-13 2013-03-13
US61/780,574 2013-03-13
PCT/US2014/026857 WO2014160499A2 (en) 2013-03-13 2014-03-13 Methods and compositions for detecting pancreatic cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020001856A Division JP7109008B2 (ja) 2013-03-13 2020-01-09 膵臓がんを検出するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2016519285A JP2016519285A (ja) 2016-06-30
JP2016519285A5 JP2016519285A5 (enExample) 2017-03-30
JP6646571B2 true JP6646571B2 (ja) 2020-02-14

Family

ID=50933479

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016502266A Expired - Fee Related JP6646571B2 (ja) 2013-03-13 2014-03-13 膵臓がんを検出するための方法および組成物
JP2020001856A Active JP7109008B2 (ja) 2013-03-13 2020-01-09 膵臓がんを検出するための方法および組成物
JP2022109693A Withdrawn JP2022141755A (ja) 2013-03-13 2022-07-07 膵臓がんを検出するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020001856A Active JP7109008B2 (ja) 2013-03-13 2020-01-09 膵臓がんを検出するための方法および組成物
JP2022109693A Withdrawn JP2022141755A (ja) 2013-03-13 2022-07-07 膵臓がんを検出するための方法および組成物

Country Status (7)

Country Link
US (3) US20160033511A1 (enExample)
EP (1) EP2972375A2 (enExample)
JP (3) JP6646571B2 (enExample)
AU (3) AU2014243704A1 (enExample)
CA (1) CA2902841A1 (enExample)
HK (1) HK1214652A1 (enExample)
WO (1) WO2014160499A2 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE534415T1 (de) 2005-12-13 2011-12-15 Harvard College Gerüste zur zelltransplantation
EP3851856A3 (en) 2007-03-27 2021-11-03 Immunovia AB Method, array and use thereof
SI2624873T1 (sl) 2010-10-06 2020-07-31 President And Fellows Of Harvard College Injektabilni, pore-formirajoči hidrogeli za celične terapije - na osnovi materialov
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
JP2014526682A (ja) 2011-09-12 2014-10-06 クリエイティクス エルエルシー 標的分子を検出する非侵襲的方法
EP2836512B1 (en) 2012-04-11 2018-10-24 F.Hoffmann-La Roche Ag Improved antibody light chains
EP3662896B1 (en) 2012-04-16 2024-02-28 President and Fellows of Harvard College Mesoporous silica compositions for modulating immune responses
MX360236B (es) 2012-06-27 2018-10-26 Berg Llc Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
JP6184581B2 (ja) 2013-03-15 2017-08-23 シャイア バイロファーマ インコーポレイテッド C1エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのc1−inh組成物ならびに方法
JP6652916B2 (ja) * 2013-06-20 2020-02-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 膵臓がんを診断するための方法
JP6759104B2 (ja) 2014-04-04 2020-09-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 精密分子質量を用いた免疫グロブリンのアイソタイピング
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
WO2015182218A1 (ja) * 2014-05-26 2015-12-03 オリンパス株式会社 膵癌判定方法
KR20160045547A (ko) * 2014-10-17 2016-04-27 에스케이텔레콤 주식회사 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법
SG10202012249YA (en) 2014-12-08 2021-01-28 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
US11054425B2 (en) 2014-12-19 2021-07-06 Roche Sequencing Solutions, Inc. System and method for identification and characterization of transglutaminase species
JP6757319B2 (ja) 2014-12-19 2020-09-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 微生物トランスグルタミナーゼ、その基質、およびその使用方法
JP6615895B2 (ja) * 2014-12-19 2019-12-04 エフ.ホフマン−ラ ロシュ アーゲー トランスグルタミナーゼ基質の同定およびそれに関する使用
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
US20160271120A1 (en) * 2015-03-17 2016-09-22 Oakdene Holdings Llc Pharmaceutical composition for cleansing of the gastrointestinal tract
GB201505654D0 (en) * 2015-04-01 2015-05-13 Nordic Bioscience As Immunoassay for collagen type VI sequence
WO2016164593A1 (en) * 2015-04-07 2016-10-13 President And Fellows Of Harvard College Compositions and methods for modulating hydroxylation of acc2 by phd3
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
EP3286218B1 (en) * 2015-04-20 2022-11-30 Consejo Superior de Investigaciones Cientificas Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 rgd motif
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
HK1254866A1 (zh) 2015-06-25 2019-07-26 Immatics Biotechnologies Gmbh 用於骨髓瘤和其他癌症免疫治疗的新型细胞表位和细胞表位组合物
WO2017036369A1 (en) * 2015-09-03 2017-03-09 The University Of Hong Kong A monoclonal antibody for predicting tamoxifen response in breast cancer patients
CN105296613A (zh) * 2015-09-24 2016-02-03 郑州市职业病防治院 一种人TERF1基因rs3863242位点多态性检测技术
CN108026164A (zh) 2015-09-24 2018-05-11 梅约医学教育与研究基金会 通过质谱鉴定免疫球蛋白游离轻链
WO2017095632A1 (en) * 2015-11-30 2017-06-08 Mayo Foundation For Medical Education And Research Heatr1 as a marker for chemoresistance
CN105785013A (zh) * 2016-04-21 2016-07-20 卢连伟 一种辅助检测胰腺癌的胶体金免疫层析试纸及其制备方法
GB201608192D0 (en) * 2016-05-10 2016-06-22 Immunovia Ab Method, array and use thereof
JP7075125B2 (ja) * 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
CA3032505A1 (en) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Biomaterials for modulating immune responses
CN109863395B (zh) 2016-09-07 2023-05-23 梅约医学教育与研究基金会 分子量法鉴定和监测裂解免疫球蛋白
CN107655985B (zh) * 2017-08-25 2020-05-26 南京农业大学 一种基于lc-ms-ms技术的体内蛋白质营养的评价方法
US12153052B2 (en) 2017-09-13 2024-11-26 Mayo Foundation For Medical Education And Research Identification and monitoring of immunoglobulin J chains
US11946937B2 (en) 2017-09-13 2024-04-02 Mayo Foundation For Medical Education And Research Identification and monitoring of apoptosis inhibitor of macrophage
AU2019247747A1 (en) * 2018-04-03 2020-09-24 Creatics Llc Methods for cancer detection by evaluation of glycan-binding patterns of immunoglobulins in gastrointestinal lavage fluid samples
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
WO2020101878A2 (en) * 2018-10-29 2020-05-22 The Johns Hopkins University Rasopathy treatment
WO2020223646A1 (en) * 2019-05-02 2020-11-05 Creatics Llc Methods for cancer detection by evaluation of alpha-1-antitrypsin (aat) and chymotrypsin-like elastase in gastrointestinal lavage fluid samples
US20220251625A1 (en) * 2019-06-24 2022-08-11 Urteste S.A. Novel diagnostic marker for pancreatic cancer
JP2022549270A (ja) 2019-09-23 2022-11-24 プレジデント アンド フェローズ オブ ハーバード カレッジ バイオマテリアルベースの無抗原ワクチンおよびその使用
US20220397576A1 (en) * 2019-10-18 2022-12-15 Reccan Diagnostics Ab Apparatuses and methods for detection of pancreatic cancer
JP7693718B2 (ja) * 2020-05-26 2025-06-17 エフ. ホフマン-ラ ロシュ アーゲー 定量器-確認器比チェックのために顧客質量分析機器を較正するためのコンピュータ実装方法
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
KR102448586B1 (ko) * 2020-10-08 2022-09-27 가톨릭대학교 산학협력단 췌장암 환자의 항암제 치료 반응성 예측용 마커
CN112461915B (zh) * 2020-12-08 2024-07-12 杭州汇健科技有限公司 一种与药物敏感相关的特征分子筛选、药敏程度检测、细胞亚型检测的方法
WO2022125482A1 (en) * 2020-12-08 2022-06-16 Memorial Sloan Kettering Cancer Center Antibodies to galectin-3 and methods of use thereof
JP2024505333A (ja) 2020-12-21 2024-02-06 フリーノム ホールディングス,インク. 結腸細胞増殖障害の早期検出のためのマーカー
US20240229154A9 (en) * 2021-02-12 2024-07-11 Institut National de la Santé et de la Recherche Médicale Method for prognosis and treating a patient suffering from cancer
US20240201166A1 (en) * 2021-04-11 2024-06-20 Vikas Khurana Diagnosis and treatment of congestive colon failure (ccf)
CA3221544A1 (en) * 2021-06-07 2022-12-15 Adrienne Marie Rothschilds Compositions and methods for targeted delivery of therapeutic agents
US12152280B2 (en) 2021-09-20 2024-11-26 Droplet Biosciences, Inc. Drain fluid for diagnostics
WO2023044117A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Drain fluid for diagnostics
US12416626B2 (en) 2022-07-22 2025-09-16 Droplet Biosciences, Inc. Methods for evaluating candidate therapy efficacy based on changes in lymphatic fluid biomarkers
WO2024086298A2 (en) * 2022-10-20 2024-04-25 The Johns Hopkins University Hla class i and class ii-restricted t-cell epitopes in pancreatic cancer tissues and uses thereof
WO2024206856A2 (en) * 2023-03-30 2024-10-03 Thomas Jefferson University Dna-dependent synthesis of rna by dna polymerase theta variants

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114818B1 (en) * 1982-08-09 1987-08-12 Centocor, Inc. Immunoassay for carbohydrate antigenic determinant
JPH0673470B2 (ja) * 1986-07-15 1994-09-21 協和醗酵工業株式会社 抗ヒト胃癌単クロ−ン性抗体amc−462
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US6924153B1 (en) 1997-03-06 2005-08-02 Quidel Corporation Quantitative lateral flow assays and devices
JPH11225800A (ja) * 1998-02-10 1999-08-24 Kureha Chem Ind Co Ltd 体液を用いた癌検出方法及びキット
US6447763B1 (en) * 1998-06-12 2002-09-10 Ian L. Gordon Method and system for production and collection of lavage induced stool (LIS) for chemical and biologic tests of cells
EP1298205A4 (en) * 2000-07-03 2004-06-16 Mochida Pharm Co Ltd NEW LIPASE
WO2003014298A2 (en) * 2001-08-03 2003-02-20 Origene Technologies, Inc. Full-length prostate selective polynucleotides and polypeptides
US7291324B2 (en) * 2002-10-22 2007-11-06 Braintree Laboratories Inc. Method of bowel cleansing
WO2004055519A2 (en) * 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
EP1718192A4 (en) * 2003-11-26 2010-07-14 Dana Farber Cancer Inst Inc ANIMAL MODELS FOR THE ADENOCARCINOM OF PANCREAS AND USES THEREOF
EP1766412B1 (en) 2004-05-21 2009-04-01 The Institute for Systems Biology Compositions and methods for quantification of serum glycoproteins
JP2009528507A (ja) 2006-03-02 2009-08-06 オンコセラピー・サイエンス株式会社 Reg4タンパク質を用いて膵癌を診断する方法
ES2522542T3 (es) * 2008-02-15 2014-11-17 Mayo Foundation For Medical Education And Research Detección de neoplasia a partir de una muestra de heces
US20090258090A1 (en) 2008-04-11 2009-10-15 Braintree Laboratories, Inc. Colon cleansing solution
JP5312684B2 (ja) * 2009-05-04 2013-10-09 エフ.ホフマン−ラ ロシュ アーゲー 癌のマーカーとしてのdppiv/セプラーゼの使用
WO2011027311A2 (en) * 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
JP2013510094A (ja) * 2009-11-05 2013-03-21 ユニバーシティ オブ バージニア パテント ファウンデーション がんのバイオマーカーとしてプレクチン−1を検出するための組成物および方法
EP3355057A3 (en) * 2010-06-01 2018-12-12 Metanomics Health GmbH Means and methods for diagnosing pancreatic cancer in a subject
MX350533B (es) * 2010-08-13 2017-09-08 Somalogic Inc Biomarcadores de cancer pancreatico y usos de los mismos.
AU2011351990A1 (en) * 2010-12-29 2013-07-18 Expression Pathology, Inc. Protein biomarkers of recurrent breast cancer
JP5984795B2 (ja) * 2011-04-05 2016-09-06 オリンパス株式会社 膵疾患を検出するためのデータを収集する方法
JP2014526682A (ja) * 2011-09-12 2014-10-06 クリエイティクス エルエルシー 標的分子を検出する非侵襲的方法

Also Published As

Publication number Publication date
WO2014160499A2 (en) 2014-10-02
EP2972375A2 (en) 2016-01-20
CA2902841A1 (en) 2014-10-02
JP2016519285A (ja) 2016-06-30
JP2022141755A (ja) 2022-09-29
US20160033511A1 (en) 2016-02-04
US20220128563A1 (en) 2022-04-28
AU2022224782A1 (en) 2022-09-22
US20190234951A1 (en) 2019-08-01
HK1214652A1 (zh) 2016-07-29
AU2020202066B2 (en) 2022-06-02
AU2020202066A1 (en) 2020-04-09
JP7109008B2 (ja) 2022-08-10
JP2020091295A (ja) 2020-06-11
WO2014160499A3 (en) 2015-01-29
AU2014243704A1 (en) 2015-09-10

Similar Documents

Publication Publication Date Title
JP7109008B2 (ja) 膵臓がんを検出するための方法および組成物
JP2014526682A (ja) 標的分子を検出する非侵襲的方法
Chen et al. Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia
US10509034B2 (en) Bladder carcinoma biomarkers
US20190170769A1 (en) Methods and compositions for detecting endometrial or ovarian cancer
JP2008014937A (ja) 腫瘍マーカー及び癌疾病の罹患の識別方法
US20090280512A1 (en) Tumor marker for renal cancer and method for determination of occurrence of renal cancer
JP2017526896A (ja) 補体因子bタンパク質に特異的に結合する抗体及び糖鎖抗原19−9タンパク質に特異的に結合する抗体を含む膵臓癌診断用キット
WO2021045180A1 (ja) 胃がんマーカー、及びこれを用いた検査方法
WO2019242741A1 (en) Biomarkers for urothelial carcinoma and applications thereof
JP2021520493A (ja) 胃腸洗浄液試料における免疫グロブリンのグリカン結合パターンを評価するがん検出方法
EP2312320B1 (en) Method for determining the stage of interstitial pneumonitis by determining PGE-MUM levels and reagent kit therefore
JP4795353B2 (ja) 腫瘍疾患および慢性炎症性腸疾患の診断のための液性バイオマーカーとしてのカルバモイルリン酸合成酵素1(cps1)の使用
JP7173815B2 (ja) 標的分子を検出する非侵襲的方法
KR20180117918A (ko) Mfap5 측정 제제를 포함하는 대장암 진단용 조성물, 키트, 및 이를 이용한 대장암 진단 방법
WO2020223646A1 (en) Methods for cancer detection by evaluation of alpha-1-antitrypsin (aat) and chymotrypsin-like elastase in gastrointestinal lavage fluid samples
WO2022091793A1 (ja) 糞便由来タンパク質を用いた膵臓がんバイオマーカーの開発
JP2017151125A (ja) 標的分子を検出する非侵襲的方法
US20200408780A1 (en) Diagnostic for sjorgren's syndrome based on a biomarker
Dutta et al. W1894 Elevated Plasma HSP70 in Patients with Pancreatic Cancer: A New Biomarker
Wang et al. W1896 Prospective Randomized Multicenter Study of FISH in Patients with Barrett's Esophagus (BE)
Goodbrand et al. W1897 Colorectal Cancer Biomarker Discovery Using Quantitative Proteomics
Venerito et al. W1895 Helicobacter pylori Infection, Gastric Atrophy and the Risk for Oesophageal Squamous Cell Carcinoma in Germany
Fu et al. W1898 Effect of Secreted Protein, Acidic and Rich in Cysteine in the AOM/DSS Mouse Model of Colitis-Induced Tumourogenesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170227

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190606

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200110

R150 Certificate of patent or registration of utility model

Ref document number: 6646571

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees